Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine

References

• World Health Organization. WHO 2003; [http://www.who.int/mediacentre/factsheets/fs211/en]. Fact sheet no 211
   Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179 - 186
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333 - 1340
   PubMed Web of Science ®Google Scholar
• Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007; 25:846 - 855
   PubMed Web of Science ®Google Scholar
• O'Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam A, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 2004; 113:585 - 593
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2007. MMWR 2007; 56:1 - 54
   PubMedGoogle Scholar
• Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655 - 1663
   PubMed Web of Science ®Google Scholar
• Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; 1269
   Google Scholar
• Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009; 9:2
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25:2842 - 2851
   PubMed Web of Science ®Google Scholar
• Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A, et al. Influenza vaccine effectiveness among 50–64 year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States 2003–2004. Vaccine 2007; 25:154 - 160
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159 - 1169
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the communitydwelling elderly. N Engl J Med 2007; 357:1373 - 1381
   PubMed Web of Science ®Google Scholar
• Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20:1831 - 1836
   PubMed Web of Science ®Google Scholar
• Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21:1769 - 1775
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin J, Mullooly J. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons. Vaccine 2006; 24:1562 - 1568
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118:68 - 77
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2008. MMRW 2008; 57:1 - 60
   Google Scholar
• Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin 2005; 1:239 - 244
   PubMed Web of Science ®Google Scholar
• Baras B, Bouveret N, Devaster JM, Fries L, Gillard P, Sänger R, et al. A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respi Viruses 2008; 2:251 - 260
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Keitel WA. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines 2008; 7:713 - 719
   PubMed Web of Science ®Google Scholar
• Hehme NW, Künzel W, Petschke F, Turk G, Raderecht C, Van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002; 22:751 - 769
   Web of Science ®Google Scholar
• Rose GW, Cooper CL. Fluarix, inactivated split-virus influenza vaccine. Expert Opin Biol Ther 2006; 6:301 - 310
   PubMed Web of Science ®Google Scholar
• Weinberger B, Keller M, Fischer KH, Stiasny K, Neuner C, Heinz FX. Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50–90 years. Vaccine 2010; 28:3511 - 3515
   PubMed Web of Science ®Google Scholar
• Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 2003; 21:3623 - 3628
   PubMed Web of Science ®Google Scholar
• Kaml M, Weiskirchner I, Keller M, Luft T, Hoster E, Hasford J, et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006; 24:6808 - 6811
   PubMed Web of Science ®Google Scholar
• Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46:1078 - 1084
   PubMed Web of Science ®Google Scholar
• Belongia E, Kieke B, Coleman L, Donahue J, Irving S, Meece J, et al. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine—Marshfield, Wisconsin 2007–08 influenza season. MMWR 2008; 57:393 - 397
   PubMedGoogle Scholar
• Strickler JK, Hawksworth AW, Myers C, Irvine M, Ryan MA, Russell KL. Influenza vaccine effectiveness among US military basic trainees 2005–06 season. Emerg Infect Dis 2007; 13:617 - 619
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take?. J Infect Dis 2008; 198:632 - 634
   PubMed Web of Science ®Google Scholar
• Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective randomized placebo-controlled trial. J Infect Dis 2009; 200:1861 - 1869
   PubMed Web of Science ®Google Scholar
• Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for laboratory-based influenza surveillance 1982; Atlanta Centers for Disease Control and Prevention and Pan-American Health Organization 17 - 35
   Google Scholar